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Abstract
This topic explores current treatments of cardiovascular diseases; what treatment 
outcomes emanate from current drug treatment. It also covers the reasons why many 
studies show poor treatment outcomes. It deals with adverse drug reaction and their 
drug management where necessary. Current cost effective interventions includ-
ing prevention strategies including drug treatments are discussed. Issues relating 
to patients’ knowledge about medication and benefits of adhering to treatment, 
method of delivery of patient information, are dealt with in detail. It highlights the 
issues of barriers to adherence to drug treatment and non-drug life style modifica-
tions. It also deals with dispensing models that encourage adherence to medication. 
It explores reasons for late diagnosis and treatment. This chapter will be informed by 
current studies published in Africa and elsewhere.
Keywords: treatment, adherence, knowledge, cost – effective analysis, dispensing 
models, late diagnosis, treatment outcomes
1. Introduction
According to the World Health Organization (WHO), Non-Communicable 
Diseases (NCDs) refers to the non-infectious and the non-transmissible medical 
conditions or diseases. These diseases generally progress slowly and are of long dura-
tion. The prevalence of NCDs and risk factors varies considerably between coun-
tries, urban/rural location and other sub-populations [1]. The four main types of 
NCDs are cardiovascular diseases, cancers, chronic respiratory diseases and diabetes. 
Globally, NCDs are the leading causes of deaths; accounting for over 70% of world 
deaths (56 million in 2015). Some of these deaths are regarded premature as 27% of 
these deaths occur in people aged between 30 and 70 years. It has been found that 
80% of these premature deaths occur in the low-and middle-income countries.
The World Health Organization estimates that mortality due to NCDs will rise by 
17% globally in the next decade; while the African region only will experience 27% 
increase by 2030. Some African countries such as Algeria (76%), Egypt (84%), Libya 
(72%), Mauritius (89%), Morocco (80%), Sao Tome and Principe (55%), Seychelles 
(81%), South Africa (51%), Sudan (52%) and Tunisia (86%) have already witnessed 
over 50% deaths attributed to NCDs since 2018 [2]. Deaths solely attributed to 
cardiovascular disease (CVD) are the leading almost globally of all other NCDs. The 
implications to the increasing prevalence of NCDs are that NCDs will soon be the 
leading causes of illness, disability and death (including premature deaths) in Africa.
There are eight behavioral and physiological risk factors associated with high 
and continually increasing burden of NCDs, namely, tobacco use, harmful use 
Lifestyle and Epidemiology - The Double Burden of Poverty and Cardiovascular Diseases...
2
of alcohol, consumption of unhealthy diet, physical inactivity, overweight and 
obesity, high blood pressure, raised blood glucose and raised total cholesterol in 
blood [3]. Since 2011, NCDs have been elevated onto global, regional and national 
development agendas through a series of political commitments. These include the 
2011 United Nations (UN) Political Declaration on NCD Prevention and Control, 
2011 Brazzaville Declaration on NCD Prevention and Control in the WHO African 
Region, WHO Global NCD Action Plan 2013–2020, 2025 Global NCD targets and 
2015 Sustainable Development Goals [4, 5].
With the above global and regional background of NCDs and initiatives, the aim 
of this chapter is to.
2. Cardiovascular diseases
Cardiovascular diseases (CVDs) refers to a group of disorders affecting the heart 
and the blood vessels supplying the heart itself (coronary heart disease, rheumatic 
heart disease, and congenital heart disease), the brain (cerebrovascular disease), 
the arms and legs (peripheral artery disease, deep vein thrombosis and pulmonary 
embolism) [6]. Cardiovascular diseases are usually associated with a build-up of 
fatty deposits inside the arteries (atherosclerosis) and increasing the risk of blood 
clotting and vessel damage; leading to heart attacks and strokes [7]. Depending on 
the organ by which blood vessels are damaged, CVDs are also associated with eye, 
brain, kidney and heart diseases.
More often, CVDs may not have symptoms relating to underlying disease to 
blood vessels; but heart attack and stroke as usually the first warning of underlying 
CVD. Heart attack, also known as myocardial infarction, occurs because of failure 
to supply oxygen-rich blood to a certain part of the heart muscle due to blockade 
of the blood vessels supplying that part; leading to muscle cell death in that oxygen 
deprived area (infarct) [8]. Heart attack manifests as sharp chest pain and discom-
fort at the center of the chest; radiating to the arms, left shoulder, elbows, jaw and 
back. During the attack episode, the person may also have trouble in breathing. 
According to Centers for Disease Control, similar to heart attack, stroke occurs 
because of failure to supply oxygen-rich blood to a certain part of the brain due to 
blockade of the blood vessels supplying that part; and bursting of the blood vessel 
in the brain; leading to death of that part of the brain that is deprived of oxygen-
rich blood [9]. Strokes are characterized by sudden symmetrical weakness of the 
limbs, face. The person experiences confusion, difficulty in speaking, vision, walk-
ing and there is loss of balance, coordination and unconsciousness may happen.
According to Plotnikoff and Dusek, hypertension (HTN) is the most important 
risk factor to getting ill and dying from a CVD [10]. The World Health Organization 
defined hypertension, also known as high blood pressure (BP), as the condition 
in which the blood vessels have persistently high pressure. The blood pressure is 
increased by the sympathetic nervous system and the renin-aldosterone-angio-
tensin system (RAAS). A drop in blood pressure is detected by pressure-sensitive 
receptors (baroceptors) which send signals to the cardiovascular centers in the 
spinal cord. This prompts a reflex response of increased sympathetic nervous 
system activity on the heart and blood vessels; resulting in increased cardiac output 
and vasoconstriction. The baroceptors in the kidneys respond to a decrease in blood 
pressure by releasing the enzyme hormone called renin. Renin converts angioten-
sinogen component of blood to angiotensin I; that ultimately gets converted to 
angiotensin II by angiotensin converting enzyme (ACE). Angiotensin II is a potent 
vasoconstrictor, constricting both arteries and veins. The activity of both sympa-
thetic nervous system and RAAS result in increase in blood pressure [11].
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The seventh report of the Joint National Committee on Prevention, Detection, 
Evaluation and Treatment of High Blood Pressure (JNC 7) define a normal BP as less 
than 120 mm Hg systolic and less than 80 mm Hg diastolic. If left uncontrolled and 
untreated, high blood pressure can result in an enlargement of the heart, heart attack, 
heart failure and eventually to death. Hypertension is also associated with loss of 
vision, cognitive and erectile dysfunction. The higher the pressure above normal, the 
greater is the risk of complications [12]. Hypertension is the culprit with end-organ 
damage in terms of all CVDs (stroke, kidney failure and peripheral vascular disease).
3. Current treatments of CVDs
Despite advances made to the treatment and prevention, CVDs are still the leading 
causes of death of all NCDs. Nevertheless, majority of CVDs are preventable with 
just lifestyle changes alone. An integrative approach has been adopted to the preven-
tion and treatment of CVDs; as the approach address the root causes influenced by 
lifestyle. The approach acknowledges that the great value and potential life-saving 
benefits of modern pharmacology and procedures cannot use only one approach since 
each has own limitation [13]. The combinatory approach allows for counteracting 
limitations of one approach with the other approach. The goal of treating CVDs is to 
improve cardiovascular health and reduce deaths from heart disease and stroke.
4. Therapeutic lifestyle changes (TLCs)
Therapeutic lifestyle changes are the foundation for non-drug management of 
HTN and/or CVD. These include smoking cessation, reduced intake of sodium diet, 
the Dietary Approach to Stop Hypertension (DASH), body weight management, 
moderation of alcohol consumption and physical activity. The American Diabetes 
Association (ADA) 2020 standards of medical care recommend that for patients with 
blood pressure > 120/80 mmHg, lifestyle intervention consists of weight loss if over-
weight or obese, DASH-style eating pattern including reducing sodium and increasing 
potassium intake, moderation of alcohol intake, and increased physical activity [14].
4.1 Smoking cessation
Smoking increases the risk of developing serious health problems and death. It is 
estimated that there are 1.1 billion people who smoke and 80% of them come from 
the low-to-middle income countries (LMICs). Further estimates reveal that smok-
ers are likely to develop heart disease and stroke 2–4 times higher compared to non-
smokers. The Table 1 below is a summary of the health benefits of quitting smoking 
from 20 minutes to 15 years adapted from the forefront UChicago Medicine [15].
4.2 Reduced intake of sodium diet
High sodium intake, estimated at >2 grams per day which is equivalent to 5 
grams of table salt per day, contributes to high blood pressure and increases risk 
of heart disease and stroke. If global salt intake could be reduced to recommended 
levels, an estimated 2.5 million deaths could be prevented [16]. In a systematic 
review and meta regression done on salt intake in sub-Saharan Africa, the results of 
the study revealed high sodium intake in many adult population (and some popula-
tions of children) above the 2 g intake recommended as the upper limit established 
by WHO [17].
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There is a strong content-dependent relationship between raised blood pressure 
and consumption of high amounts of sodium. Dietary guidelines recommend a daily 
intake of sodium at less than 2.3 grams in the general population and less than 1.5 
grams in people with high blood pressure, diabetes, kidney disease and those aged 
50 years old or more. Salt reduction initiates a decline in average blood pressure in a 
week time. It also improves the body response blood pressure medicines. Lowering 
blood pressure reduces risk of heart disease, stroke and death due to salt related CVDs.
4.3 The DASH eating plan
The pioneer trial that examined the role of diet in the management of hyperten-
sion was the DASH trial in 1997. The results of the trial revealed that after approxi-
mately 3 g sodium intake per day on both control and interventional group; within 
2 weeks of the intervention, blood pressures reduced and the results sustained for 
another 6 weeks. Systolic blood pressure (SBP) reduced by 5.5 mm Hg and diastolic 
blood pressure (DBP) by 3.0 mm Hg more than the control diet [18].
The DASH eating plan entails a diet rich in fruits and vegetables (8–10 servings/
day); and low-fat dairy foods (2–3 servings/day), coupled with reduced saturated 
and total fat [19]. DASH is a flexible and balanced eating plan that helps create a 
heart-healthy eating style for life. The DASH eating plan requires no special foods 
and instead provides daily and weekly nutritional goals. DASH eating plan recom-
mends that the choice of foods should also be based on food that are:
• Rich in potassium, calcium, magnesium, fiber (roughage) and protein
• Low in saturated fat (animal fat) and trans-fats (from snacks)
• Lower in sodium (table salt, flavourants, spices, processed foods including 
water)
Globally, calories obtained from Proteins, Sugars and Fats have been increas-
ing and those from roughage-rich foods have been declining. Consumption of 
processed foods continues to rise rapidly in low- and middle-income settings. This 
nutrition transition affects dietary patterns and nutrient intake, which influence the 
risk of developing NCDs.
Time of quitting 
smoking
Extent of body recovery
20 minutes Heart rate and blood pressure drops
24 hours Chance of heart attack decreases
2–12 weeks Blood circulation improves and lung function improves
1–9 months Cough, difficulty in breathing and sinus congestion are lowered
1 year Risk of heart disease drops to half compared to that of a smoker
5 years Risk of cancers of the mouth, throat, gullet and bladder are cut by half.
Stroke risk is reduced to that of a nonsmoker 5 to 15 years after quitting.
10 years Risk of lung cancer drops to half compared to that of a smoker and risk of cancer of 
the mouth, throat, esophagus, bladder, cervix, and pancreas decreases.
15 years Risk of heart disease is equal to that of a non-smoker
Table 1. 
Time of quitting smoking and extent of body recovery.
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DASH diet is one among such healthy dietary patterns, which emphasizes on;
• Consumption of fruits, vegetables and low-fat dairy foods.
• Whole grains, poultry, fish, and small quantities of red meat, sweets and 
drinks containing sugar.
• The increased risk of cardiovascular diseases associated with higher sodium 
intake (>5 g/day) is most prominent in those with high blood pressure.
4.4 Body weight management
Overweight and obesity are major risk factors for a number of chronic diseases, 
including CVDs such as heart disease and stroke, which are the leading causes of 
death worldwide. Globally, obesity is one side of the double burden of malnutrition, 
and today more people are obese than underweight in most regions of the world. A 
body mass index (BMI) over 25 kg/m−2 is considered overweight, and over 30 kg/
m−2 is obese. The issue has grown to epidemic proportions, with over 4 million 
people dying each year as a result of being overweight or obese in 2017 according to 
the global burden of disease [20]. Nevertheless, modest weight losses of 5 to <10% 
were associated with significant improvements in CVD risk factors at one year, but 
larger weight losses had greater benefits [21].
4.5 Moderation of alcohol consumption
The Centers for Disease Control and Prevention (CDC) define alcohol modera-
tion as having up to one drink per day for women and up to two drinks per day for 
men. The definition refers to the amount consumed on any single day and is not 
intended as an average over several days [22]. However, it is not recommended 
that that people who do not drink alcohol start drinking for any reason. Excessive 
alcohol intake includes binge drinking, heavy drinking and any alcohol use dur-
ing pregnancy. Binge drinking corresponds to five or more drinks in men and four 
or more drinks in women on a single occasion, generally within two hours; while 
heavy drinking is defined as consuming 15 drinks or more per week for men and 
eight drinks or more per week in women. In 2019, top nine African countries with 
high alcohol consumption in liters per capita were in the order of Nigeria, Eswatini, 
South Africa, Lesotho, Zimbabwe, Zambia, Malawi, Ghana and Morocco [23]. 
Excessive alcohol consumption increases the risk of developing heart disease by 
increasing BP and weakening heart muscles [24].
4.6 Physical activity
Globally, lack of sufficient physical activity is the fourth risk factor to develop-
ment of NCDs. While physical inactivity is attributed to prevalence of diabetes 
at 27%, heart diseases caused by heart vessels blockage at 30% and breast and 
colon cancer at 21–25%; 3.2–5 million deaths globally are associated with physical 
inactivity [25]. The World Health Organization defines physical activity as a bodily 
movement produced by muscular and skeletal body systems which require energy 
expenditure. In other words, physical activity encompasses all activities undertaken 
while working, playing, carrying out household chores, traveling, recreation; in 
addition to exercise activities. Physical activity is further classified as moderate- 
and vigorous-intensity physical activity. Also, physical activities are sub-classified 
as aerobic (those that engage large muscles of the hands and legs; making the 
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heartbeat and breathing rate to be faster than normal), muscle-strengthening 
(those that improve the strength, power, and endurance of your muscles) and bone-
strengthening (those that strengthen feet, legs arm to support body weight) [26].
In order to gain health benefits of physical activity; it is recommended that 
children and adolescents should do at least 60 minutes of moderate to vigorous-
intensity physical activity daily; while adults should do at least 150 minutes of 
moderate-intensity physical activity throughout the week, or at least 75 minutes of 
vigorous-intensity physical activity throughout the week. Those with poor mobility 
should perform physical activity to enhance balance and prevent falls, three or more 
days per week. The general rule is that two minutes of moderate-intensity activ-
ity counts the same as one minute of vigorous-intensity activity and the exercise 
should continue up to sweating [27].
Regular and sufficient levels of physical activity are attributed to the following 
cardiovascular benefits;
• Strengthened heart
• Reduced risk of heart attack
• Reduced risk of hypertension (high blood pressure), heart diseases, stroke, 
diabetes, various types of cancer (including breast and colon) and depression.
• Maintained healthy body weight control
• Reduced blood cholesterol level
5. Pharmacological treatment of CVDs in Africa
According to Rizos and Elisaf [28] hypertensive patients with African ancestry 
are a distinctive population of patients that presents with some unique characteris-
tics. These patients commonly have increased incidence and early onset of hyper-
tension and often-poor BP control. They often present at healthcare facilities with 
additional concomitant CVD risk factors.
The ADA 2020 standards on pharmacological interventions to CVDs recom-
mend the following:
Patients with confirmed office based blood pressure ≥ 140/90 mmHg should, in 
addition to lifestyle therapy, have prompt initiation and timely titration of pharma-
cologic therapy to achieve blood pressure goals.
This is strongly emphasized in the African ancestry population that appropriate 
TLCs and combination of diuretic and/or calcium channel blocker (CCB) should 
be initiated promptly. In African black populations, patients receive aggressive 
treatment at lower BPs compared to non-African, non-black counterparts who are 
recommended initial combination therapy when they fit the requirement below.
Patients with confirmed office based blood pressure ≥ 160/100 mmHg should, 
in addition to lifestyle therapy, have prompt initiation and timely titration of two 
drugs or a single-pill combination of drugs demonstrated to reduce cardiovascular 
events in patients with diabetes.
Treatment for hypertension should include drug classes demonstrated to reduce 
cardiovascular events in patients with diabetes (ACE inhibitors, angiotensin recep-
tor blockers, thiazide-like diuretics, or dihydropyridine calcium channel blockers).
Whites generally responded better to β-blockers and ACE inhibitors whereas 
blacks generally responded better to diuretics and calcium channel blockers [29].
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Multiple-drug therapy is generally required to achieve blood pressure targets. 
However, combinations of ACE inhibitors and angiotensin receptor blockers and 
combinations of ACE inhibitors or angiotensin receptor blockers with direct renin 
inhibitors should not be used.
Pharmacologically ACE inhibitors, angiotensin receptor blockers and renin 
inhibitors act on the renin-aldosterone-angiotensin system to lower the cardiac pre- 
and after-load. So giving one class will be sufficient; although black populations 
generally respond poorly to ACE inhibitors [29].
An ACE inhibitor or angiotensin receptor blocker, at the maximum tolerated 
dose indicated for blood pressure treatment, is the recommended first-line treat-
ment for hypertension in-patients with diabetes and urinary albumin-to-creatinine 
ratio ≥ 300 mg/g creatinine or 30–299 mg/g creatinine. If one class is not tolerated, 
the other should be substituted.
For patients treated with an ACE inhibitor, angiotensin receptor blocker, or 
diuretic, serum creatinine/estimated glomerular filtration rate and serum potas-
sium levels should be monitored at least annually [11].
The insufficiencies associated with availability of necessary resources to monitor 
treatment of CVDs in Low-Middle Income Countries (LMICs) are major barriers 
to having integrated healthcare system with an effective data flow. These resources 
include technological infrastructure, financial and human resources [30].
6. Phamacovigilance of antihypertensive medications
According to the World Health Organization definition, an adverse drug reaction 
(ADR) is ‘a response to a drug that is noxious and unintended and occurs at doses nor-
mally used in human for the prophylaxis, diagnosis, and treatment of disease, or for 
modification of physiological function’ [26]. Also, pharmacovigilance (PV) defined by 
WHO as “the science and activities relating to the detection, assessment, understand-
ing and prevention of adverse effects or any other drug-related problem [31].
In Africa, countries differ in terms of a having fully functional PV systems due 
to differing capacities of national medicines regulatory authorities and performance 
levels with respect to conducting various pharmacovigilance activities. Therefore, the 
system for reporting adverse drugs reactions has significant gaps to be strengthened 
from one country to another [32, 33]. However, in some settings within African coun-
tries, the following suspected ADRs were documented as indicated in Table 2 [34].
Adverse drug 
reaction
System organ classifications (Medical 




Renal and urinary disorders Diuretics, CCBs,
Dizziness Nervous system disorders Diuretics, CCBs, ACEIs, Centrally 
acting, β-blockers, α- blockers
Headaches Nervous system disorders Diuretics, CCBs, Centrally acting,
Diarrhea Gastrointestinal disorders ACEIs
Weakness Musculoskeletal and connective tissue 
disorders
Diuretics, CCBs, Centrally acting




ADRS, system organ classifications and suspected causal drug classes.
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7. Cost effectiveness of cardiovascular disease prevention and treatment
The highest age standardized death rate from non-communicable diseases 
(NCDs) (779 per 100, 000) occur mostly in the African Region [35]. In sub Saharan 
Africa, the probability of dying from NCDs between 30 and 70 years is very high. 
It is also indicated that behavioral risk factors are estimated to be responsible for 
about 80% of coronary heart disease and cerebrovascular disease and these include 
tobacco use, physical inactivity, unhealthy diet and harmful use of alcohol. The 
cost of implementing reduction measures for tobacco control (smoke-free poli-
cies, raise tobacco taxes, package warnings, advertising bans), harmful alcohol 
consumption, and physical activity and diet modification is found to be low [36]. 
Usually these costs include media campaigns and overall program management. It is 
feasible to deliver cardiovascular risk reduction interventions in primary care, even 
in low-resource settings with non-physician health workers [37]. Currently, there 
are major gaps in access to these essential primary care interventions in developing 
countries including in those in sub-Saharan Africa [38].
There are other strategies that can be employed to prevent cardiovascular dis-
eases. This becomes attractive to providers and can lead to policy change. According 
to recent surveys there is high prevalence of salt consumption [39] in South Africa. 
The burden of cardiovascular disease (CVD) in the same country is rising, and to 
address this, the government recently developed policies to reduce salt consump-
tion in the population [39]. Population-based salt reduction strategies have been 
found to be a cost-effective approach to lowering the prevalence of hypertension 
and preventing cardiovascular disease (CVD). The cost saving for both household 
and providers was significantly different. The extended cost-effectiveness analysis 
(ECEA), which models the health gains, financial risk protection and distributional 
effects of public policies.
Mathers [40] states that cardiovascular diseases are responsible for about 30% 
of all deaths worldwide, and total deaths occurring in developing countries amount 
to about 80% [41]. Several authors have suggested that the combination of several 
preventive treatments could cut more than half the occurrence of cardiovascular 
disease [41–43]. The analyses have shown that two multidrug regimens of four 
highly effective drugs could lead to cost-effective prevention and treatment for 
patients with cardiovascular disease in all developing regions [44]. Wald and Law 
[41] specifically proposed a polypill, consisting of a statin, aspirin, a β blocker, 
an angiotensin-converting-enzyme inhibitor (ACEI), a thiazide, and folic acid. 
Suggested primary preventive therapy consists of aspirin, ACEI, calcium-channel 
blocker, and statin. While secondary preventive therapy consists of aspirin, ACEI, β 
blocker, and statin [41]. If two polypills, consisting of the same drug combinations 
as the primary and secondary prevention strategies, would also improve adherence, 
the results would be even more favorable.
In conclusion, these lifestyle modification strategies such as tobacco use control, 
reduction in harmful effects of alcohol, diet and physical activity and salt intake 
reduction are perceived to be cost-effective. Primary and secondary preventive 
treatments are also found to be cost-effective in preventing cardiovascular disease. 
This can improve on patients quality of life with cost savings.
8. Patients knowledge about cardiovascular diseases and medicines
An individual must know at least 75% of the items used in the summary 
variables to qualify as having acquired adequate knowledge [45]. For those 
patients who can achieve adequate knowledge, this should be the target for having 
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comprehensive knowledge. However, in cardiovascular diseases, this may be 
affected by age, agility, and cognitive skills particularly in elderly patients.
According to Mugomeri and colleagues, nearly 36% had inadequate knowledge 
about hypertension while 44% had inadequate knowledge about their medicines 
[46]. In this study, in total, 52.4% of the patients did not turn up for appointment 
dates while 64.6% failed to take their medications according to the prescription at 
least once. It was also stated that inadequate knowledge of antihypertensive medi-
cines was significantly associated (P = .028) with having uncontrolled hypertension 
[46]. Inadequate knowledge of antihypertensive medicines is an important determi-
nant of uncontrolled hypertension [46].
The study carried out on village health workers (VHW) in Lesotho, as health 
workers, determining adequate knowledge and translation of knowledge to offered 
services indicated that among household members aged 15 years and above, only a 
third was advised by the VHW to go for HIV testing [47]. Communities served by 
VHWs with adequate knowledge did not only demonstrate better knowledge com-
pared to their counterparts served by VHWs with inadequate knowledge, in utiliza-
tion VHWs’ services were high [47]. The finding confirmed what was suggested by 
the literature of Hirsch-Moverman [48]. Community health workers (CHWs) form 
part of the primary health care system [47]. The community health workers who 
have adequate knowledge can play a very important role in their communities in 
terms of education, monitoring adherence and referrals [47]. It is therefore, recom-
mended that training of CHW on cardiovascular diseases, treatment and preven-
tion of complication be taken as a priority in the African continent.
Information is crucial to promote patients’ knowledge which increases the sense of 
control, decrease emotional distress, support effective self-management, and eliminate 
disruptions of daily activities [49, 50]. Patients want to have control over their symp-
toms therefore, they need as much information as possible about their symptoms and 
strategies to manage these symptoms. The patient knowledge about cardiovascular 
diseases leads to good management of the diseases. Bandura [51] reiterates that a con-
tributing factor to the difference in symptom self-management is a person’s perceived 
self-efficacy. Perceived self-efficacy forms the basis of any decision to act on and is 
defined as the perception of one’s own ability to implement behavior(s) to achieve 
designated types of outcomes such as symptom management. Bandura [52] further 
explains that perceived self-efficacy beliefs are considered to be central and influential 
factors in determining the course of action to be chosen, the degree of effort applied, 
and the perseverance to continue in the face of problems and obstacles.
Intervention is required in order to improve the knowledge of patients regarding 
cardiovascular diseases, hypertension, and associated medications [53, 54]. This 
intervention comprises of the patient essential educational topics and method of 
delivery of patient education. Patient education topics should include pathophysiology 
and etiology, symptoms and signs, pharmacological treatment, risk factor modifica-
tion, diet and exercise, sexual activity, immunization, sleep and breathing disorders, 
adherence, psychosocial aspects and prognosis associated with certain skills or 
self-management behaviors [54–56]. However, patient education alone is not enough, 
the delivery of patient education content should consider level literacy, age, and other 
cognitive measures. Medium of delivery of patient education must be individualized 
according to the needs of the patient. Some patients benefit from one-on-one sessions, 
while others benefit from group sessions, some still can benefit from both sessions.
The guidelines recommend patient education and counseling targeting patient 
skills and behavior [57]. For patient education to be effective Meng and colleagues [53] 
recommend outcome and measurement strategies to enlighten on primary and sec-
ondary outcomes. The primary outcome entails self-management competencies which 
are measured through self-monitoring and insight, skill and technique acquisition, 
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and self-efficacy. While secondary outcomes are measured through self-management 
health behavior (symptom control, physical activity, medication adherence), health-
related quality of life, and treatment satisfaction. Meng and colleagues [53] concluded 
that a patient-centered self-management might be more effective regarding certain 
self-management outcomes than a lecture-based usual care education.
Hinderlang [58] suggests that the material for patient education should be devel-
oped bearing in mind patients’ cultural and language barriers. Patients’ preferences 
should also be considered before embarking on patient education that may not be 
effective [59]. The content of patient education material should be broken down into 
concise, manageable sessions that do not overwhelm with vast amounts of facts and 
details and be free of medical jargon. The learning environment should be free of 
stress, environmental distractions, cultural conflicts, and value judgments all should 
be eliminated if possible. Timing should be based on the available time, attention 
span, and readiness for learning without rushing or taking too much time. The 
patients have to be actively involved in the process of learning and understand the 
value of the information and procedures being taught for improving the quality of his 
or her life [58]. Patients increasingly demand access to medical information, this has 
improved the patient-physician relationship and consequently improved patient care.
The disease management education plan should also include practical skills for 
patients and caregivers to participate in their own care. These may include:
a. Gargets to use and how to use them and what readings mean (BP machine etc.)
b. Assess patients understanding and their educational needs
c. Identify patients’ barrier to receive information
d. Need to involve a caregiver
e. How to take one’s own pulse;
f. How to take weight accurately (at the same time each day, with the same cloth-
ing on);
g. How to measure one’s blood pressure correctly (if appropriate);
h. How to manage one’s medications (which includes the name of drug; purpose it 
is used for when to take it, what to avoid and how it is stored)
i. Return with the remaining medicines in each clinic visit
j. How to lift one’s feet to reduce swelling
k. How to manage food and fluids;
l. How to manage with stress and
m. How to keep a record of weight, blood pressure and any other information on 
the diary or calendar and share with healthcare workers
n. Self-referral and preferred method of communication
In summary self-efficacy and self-management of cardiovascular diseases will 
encourage patients to be in control of their diseases, and their treatment. This will 
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improve their treatment outcome. The community health workers can provide 
education, support and referral roles particularly in rural settings.
9. Adherence to medications
Non-communicable diseases (NCDs) are chronic diseases where adherence to 
medication is essential to controlling these diseases. Patients with NCDs such as car-
diovascular diseases, diabetes mellitus and hypertension are put on long-term therapy 
to manage their conditions. The health outcomes of these patients depend mainly on 
how they adhere to medication as well as on lifestyle modification. The World Health 
Organization (WHO) defined adherence as the extent to which the behavior of a per-
son, such as taking medication, following a diet or lifestyle modification, corresponds 
with the agreed recommendations from a health care provider [60].
Although adherence is important to patients with NCDs who are on medication, 
non-adherence to medications is a concern in Africa. In a study conducted among 
patients with NCDs in Puducherry, South India, the prevalence of low adherence to 
medication was 32.7% [61]. In contrast, prevalence of poor adherence to diabetes 
mellitus medication in rural Kerala, South India was 74% [62]. A study conducted 
in a health facility in a peri-urban district in the Ashanti region of Ghana found that 
the overall prevalence of medication noncompliance among patients with chronic 
diseases was 55.5% [63]. Inadequate medication possession ratios and thereby treat-
ment adherence was observed in hypertensive patients at two private outpatient 
health clinics in Sierra Leone, with more than 80% of patients assessed not having 
medication for more than 40% of the time period studied [64]. In a specialist clinic 
and general outpatient clinic in Nigeria, the overall self-reported high medication 
adherence was low among Nigerian hypertensive subjects [65]. Adherence level of 
hypertensive patients at Jimma University specialized hospital, Ethiopia, to antihy-
pertensive medications was found to be sub-optimal due to daily alcohol intake, co-
morbidity, number of antihypertensive medications and availability of medications 
without fee [66]. A study conducted in Kampala (Uganda) among hypertensive 
stroke patients found that 17% of the patients were adherent to antihypertensive 
medications, and the main cause of non-adherence was lack of knowledge [67].
Non-adherence is when patients do not take their medications at all, are taking 
reduced amounts, or are taking doses at the prescribed frequencies but not taking 
into consideration medication to food requirements [68]. Non-adherence can either 
be intentional or unintentional. Intentional non-adherence is when a patient makes a 
rational decision not to use treatment or follow treatment recommendations [69–72]. 
Intentional adherence includes patient-related, therapy-related, and condition-
related factors [69–72]. Unintentional non-adherence is unplanned patient behavior 
and is less strongly associated with beliefs and the level of cognition as compared to 
intentional non-adherence [69–72]. Unintentional non-adherence may be caused 
by forgetfulness and not knowing when and how to take medicines [69–72]. Factors 
affecting adherence of patients to their medicines such as therapy-related and 
condition-related factors are associated with unintentional non-adherence [69–72].
Barriers of adherence to medication are discussed in the subsequent subsection and 
mainly include categories of factors affecting patients’ adherence to their medicines.
10. Barriers of adherence to medication
There are barriers of adherence to medication that affect patients with 
cardiovascular diseases, diabetes mellitus and hypertension thus, leading to 
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non-adherence. These barriers are classified into different categories of factors 
affecting adherence of patients to their medication. Categories of factors affecting 
patients’ adherence to medication in Africa include sociodemographic, economic, 
environmental, condition-related factors, therapy-related, health care team and 
system-related factors, and patient-related factors [73–79]. Sociodemographic, 
economic and environmental factors are composed of low-income, poverty, 
minority race-ethnicity, social support, copayments, and health literacy [73, 77]. 
Health care team and system-related factors include patient-clinician relationship, 
communication style, lack of team-based care, clinician burn out, lack of knowl-
edge, lack of policies, lack of ad hoc screening and proper referral systems, and 
poor universal health insurance coverage [73, 74, 76, 77, 80, 81]. Complex regimen, 
treatment changes, failure and duration, adverse effects, and refill frequency and 
consolidation are therapy-related factors [73, 78]. Condition-related factors include 
multiple chronic conditions, depression, psychoses, drug or alcohol abuse, demen-
tia, major disability, severity of symptoms, and quality of life [73]. Patient-related 
factors include perception of illness and treatment efficacy, denial of diagnosis, fear 
of dependence or adverse effects, lack of knowledge, forgetfulness, and low self-
efficacy [73, 80, 81].
Several interventions can be put in place to curb factors affecting patients’ 
adherence to medication. Therapy-related and condition-related factors could 
be minimized by prescribing few medications which can be implemented using 
once daily single-pill combinations [71]. Use of once daily single-pill combina-
tions is associated with better adherence and hypertension control [71, 82]. Also, 
clinicians can prescribe a larger number of medications with each prescription to 
reduce refill frequency [69, 71]. Patients with NCDs frequently have co-morbidities 
requiring additional medication to their medicines for NCDs thus, refill consoli-
dation so that multiple medications are obtained at the same time can improve 
adherence [69, 71].
To curb some of the health care team and system-related factors, patients should 
trust and be confident that the clinician is competent and has their best interest 
when making management decisions [73]. Patients, especially racial-ethnic minori-
ties, should actively participate in decisions about the management of their NCDs 
and what medication to take [69, 73]. Policies addressing procurement process of 
medication and control of NCDs should be developed and implemented in health 
systems [74]. Also, the use of generic medicines for NCDs and improvement of 
health insurance coverage will reduce the cost of care for patients with NCDs 
therefore, solving some of the barriers to adherence [74].
Dispensing models can be implemented to assist with monitoring adherence to 
medicines and the treatment outcome.
11. Dispensing models to assist with adherence and treatment outcome
Poor adherence to medication is a major contributor to uncontrolled cardio-
vascular diseases, diabetes mellitus and hypertension. Monitoring and detection 
of adherence of patients to their medication using different dispensing models 
assist with assessing the treatment outcome. Medication adherence can be 
measured directly or indirectly using several measurements either separately or 
together [83, 84]. Indirect measurements include pill count, patient interviews, 
prescription refills data, electronic monitoring system, directly observed tech-
nique, and questionnaire [83, 84]. Direct measurements include measurement 
of drug levels and digital medicine [83, 84]. Prescription refills data, pill count, 
directly observed technique, and electronic monitoring system are objective 
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measurement whereas, questionnaires and patient interviews are subjective 
measurements [83, 84]. Biomedical measurements consist of measurement of 
drug levels and digital medicine [83, 84].
12. Different dispensing models used to measure adherence
Dispensing models include interviewing patients, questionnaires, pill count, 
prescription refills data, electronic monitoring system, measurement of drug levels, 
digital medicine, and directly observed technique [73].
Patient’s interview is when a physician questions the patient about adherence 
to medicines. The physician asks the patient questions related to medicine-taking 
behavior thus, communication skills of the physician and the ability to conduct 
nonjudgmental discussion is important [73]. The health care professional asks the 
patient to estimate their own medication-taking behavior, such as which percentage 
of dose that they may miss within a designated period or the frequency that they are 
unable to follow the medication regime [83]. On the other hand, questions asked to 
the patient by the health care professional can be based on the patient’s knowledge 
on the prescribed regime, including drugs’ name, schedule, and indications [83]. 
Health care professionals then evaluate their response to determine the level of 
adherence [83].
Questionnaires are forms which can be completed by patients, trained nurses 
or healthcare professionals as a tool to monitor adherence [73]. Types of question-
naires used to measure adherence are the Brief Medication Questionnaire, Hill-
Bone Compliance Scale (Hill-Bone), Eight-Item Morisky Medication Adherence 
Scale (MMAS-8), Medication Adherence Questionnaire (MAQ ), Self-Efficacy for 
Appropriate Medication Use Scale (SEAMS), and the Medication Adherence Report 
Scale (MARS) [85, 86]. A well-known and mainly used questionnaire to measure 
adherence is the Morisky questionnaire [69, 83].
Pill count is a frequently used dispensing model to monitor adherence where 
counting returned pills by a patient gives an overview of what has been taken by the 
patient [73]. The health care provider counts the number of dosage units that have 
been taken by the patient between two scheduled appointments or clinic visits [83]. 
This number would then be compared with the total number of units received by 
the patient to calculate the adherence ratio [83]. The equation for calculating pill 
count is as follows: (Number of dosage units dispensed − Number of dosage units 
remained) / (prescribed number of dosage unit per day × number of days between 2 
visits) [83].
Prescription refill data requires availability of electronic monitoring of drug 
prescriptions in pharmacies [73]. Prescription refill data assists with obtaining a 
rough estimate of medicines adherence and persistence by calculating the percent-
age of days covered by the prescriptions [73]. When measuring adherence using 
prescription refills, it is assumed that prescription-refilling patterns correspond to 
the patient medication-taking behavior and that the medication is taken exactly as 
prescribed [83].
Electronic monitoring system consists of a device in which a microcircuit is 
incorporated into medication packages and any removal of a dose of the medicine is 
detected in real time, time stamped, analyzed, stored, and communicated [73, 83]. 
Commonalities of different electronic monitoring devices include (i) recorded dos-
ing events and stored records of adherence, (ii) audiovisual reminders to signal time 
for the next dose, (iii) digital displays, (iv) real-time monitoring, and (v) feed-back 
on adherence performance [83]. The commonly used electronic monitoring device is 
the Medication Event Monitoring System (MEMS) [73, 83].
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Measurement of drug levels involves the measurement of the medicine or its 
metabolite concentration in body fluids, such as blood or urine, and evaluation of 
the presence of a biological marker given with the medicine and direct observation 
of patient’s medication-taking behavior [73, 83]. Complete absence of medicine in a 
sample indicates that the medicine has not been taken by the patient for a duration 
equivalent to half-lives of the medicine [73].
Directly observed technique is an approach when medicine is given and taken 
by the patient under supervision of a member of the clinical staff every day for a 
certain period of time [73].
Digital medicine consists of ingestible sensors incorporates in the pill during 
manufacturing process, which will be ingested by the patient [73]. After ingestion, 
an electrochemical reaction is triggered in the stomach leading to an activation of 
the sensor and generating a unique message coded for the medication name and 
dose to a wearable patch worn by the patient on the torso and recorded the date 
and time of the sensor ingestion [73]. The information collected by the patch is 
encrypted and transmitted wireless to a designated device using Bluetooth. The 
sensors are then eliminated as solid waste within 72 hours [73].
There are other dispensing models used to monitor patient medication adher-
ence thus, treatment outcome. Modern technology can be used to monitor adher-
ence and includes the use of internet, real time medication monitoring (such as 
electronic pill boxes), and mobile phones [69]. The use of electronic pill boxes 
combined with Short Message Service (SMS) reminders are specifically designed 
to improve unintentional adherence [69]. These interventions have resulted in an 
increase in refill adherence in diabetic patients with suboptimal adherence [68]. 
Mobile phones can be used to send alerts to take medication to patients, track doses, 
and provide appropriate medication instructions [86]. Automatic home medication 
dispenser (AHMD) integrated with a smartphone application can be used to address 
adherence issues especially for elderly patients [86]. The AHMD holds up to 90 day’s 
supply of several medications, and addresses cognitive impairment and age-related 
changes using components such as counter, clock dispensing mechanism, power 
source, input/output interface, locking system, transceiver and antenna, and physi-
cal indicators for alarms [86]. The AHMD also notifies the patient of due dosage 
per set dosage time or due refills through audio/visual reminders, and notifies the 
caregiver of missing dosages through calls or text messages [86–88].
In conclusion, it is important to monitor adherence of patients with chronic 
diseases to their medicines using appropriate dispensing models (either alone or 
in combination) as uninterrupted life-long consumption of medicines will prove 
patients’ health outcome. In instances where non-adherence has been identified, 
it is essential to note factors affecting adherence of patients to their medicines and 
address those factors.
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